Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
L-glutamate is the major excitatory neurotransmitter in the central nervous system and activates both ionotropic and metabotropic glutamate receptors. Additionally we are shipping Metabotropic Glutamate Receptor 3 Kits (15) and Metabotropic Glutamate Receptor 3 Proteins (6) and many more products for this protein.
Showing 10 out of 81 products:
Human Polyclonal Metabotropic Glutamate Receptor 3 Primary Antibody for WB - ABIN652205
Aronica, Gorter, Rozemuller, Yankaya, Troost: Activation of metabotropic glutamate receptor 3 enhances interleukin (IL)-1beta-stimulated release of IL-6 in cultured human astrocytes. in Neuroscience 2005
Show all 5 references for ABIN652205
Mouse (Murine) Polyclonal Metabotropic Glutamate Receptor 3 Primary Antibody for IHC, WB - ABIN1742076
Conn, Pin: Pharmacology and functions of metabotropic glutamate receptors. in Annual review of pharmacology and toxicology 1997
Significant association was found between rs12704290 in GRM3 gene and schizophrenia(SCZ). A three-SNP LD spanning GRM3Delta4 splice site was significantly associated with SCZ. Interaction between the LD block and cognitive function was found in SCZ patients.
Results show that GRM3 rs274622 C carriers with schizophrenia were associated with significantly smaller prefrontal activation than patients with TT genotype
Grm3 expression was decreased in B cells from patients with autoimmune diseases such as activated systemic lupus erythematosus and multiple sclerosis.
Pharmacogenetic relationships were identified in patients with schizophrenia between GRM3 variants and symptom response to antipsychotics.
PI4KA (show PI4KA Antibodies) and GRM3 polymorphisms have potential to jointly modulate antipsychotic response
Findings suggest that mGluR2 (show GRM2 Antibodies)/3 and mGluR5s are unaltered in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia
Results demonstrate no changes in expression and density of both 5-HT2AR and mGlu2 (show GRM2 Antibodies)/3R in the postmortem prefrontal cortex of subjects with major depressive disorder under basal conditions; antidepressant treatment induces a decrease in 5-HT2AR density
The mGluR3 promoted the proliferation of human embryonic cortical NPCs and increased cyclin D1 (show CCND1 Antibodies) expression by activating ERK1/2 (show MAPK1/3 Antibodies) and JNK2 (show MAPK9 Antibodies) signaling pathways.
The data of this study suggest an association of the GRM3 rs6465084 polymorphism with changes in pursuit maintenance after antipsychotic treatment.
This study provided that the evidence for an association between GRM3 genotype and schizophrenia and suggest a role for glutamate (show GRIN1 Antibodies) neurotransmission in the establishment and maintenance of myelinated fibers.
provided evidence that JARID1B (show KDM5B Antibodies) via modulation of stemness-related signaling is a putative novel therapeutic target for treating malignant NB
Activation of GABA(B) or mGlu2 (show GRM2 Antibodies)/3 receptors inhibited both evoked presynaptic Ca(2 (show CA2 Antibodies)+) transients and striatal field potentials.
Activation of Grm3 ameliorates lupus-like disease in mice by reducing B cell numbers. Grm3 expression on B-cells is decreased in lupus-prone mice.
The number of mGluR3-immunoractive cells was significantly reduced in the dorsal and intermediate but not ventral parts of the lateral septum in postpartum versus virgin females.
GRM3-knockout mice exhibit a biphasic effect in spatial working memory, initially impaired but performing better after training.
The results of these studies implicate mGlu3 as a major regulator of PFC (show CFP Antibodies) function and cognition.
This study demonistrated that mGluR3 knockout mice show a working memory defect.
report we describe a novel neuroprotective function of mGlu3 receptors related to their ability to promote the non-amyloidogenic pathway of APP (show APP Antibodies) cleavage in astrocytes, thus enhancing sAPPalpha production
The findings support the possibility that interactions between mGlu2 (show GRM2 Antibodies)/3 and dopamine may be relevant to the pathophysiology and therapy of schizophrenia and other disorders
mGluR3 knockouts did not differ from controls in reinstatement of drug-seeking behavior, suggesting that mGluR2 (show GRM2 Antibodies) receptors are critical in mediating addictive-like behavior.
L-glutamate is the major excitatory neurotransmitter in the central nervous system and activates both ionotropic and metabotropic glutamate receptors. Glutamatergic neurotransmission is involved in most aspects of normal brain function and can be perturbed in many neuropathologic conditions. The metabotropic glutamate receptors are a family of G protein-coupled receptors, that have been divided into 3 groups on the basis of sequence homology, putative signal transduction mechanisms, and pharmacologic properties. Group I includes GRM1 and GRM5 and these receptors have been shown to activate phospholipase C. Group II includes GRM2 and GRM3 while Group III includes GRM4, GRM6, GRM7 and GRM8. Group II and III receptors are linked to the inhibition of the cyclic AMP cascade but differ in their agonist selectivities.
metabotropic glutamate receptor 3
, glutamate metabotropic receptor 3
, G protein-coupled receptor, family C, group 1, member C